RxDoctor Payments Data

Erica Jones

Family · Des Moines, IANPI 1053040584

Payments from drug & device makers

$3,227in general payments, 2019–2025

Across 88 payments — averaging $36.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • AstraZeneca$604
  • Abbott$375
  • Medtronic$310
  • Johnson & Johnson$267
  • Boehringer Ingelheim$266
  • plus $395 from 4 others

What the payments were for

  • Food & beverage$3,227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,227 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$2,264
Medicare patients
29
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$22,794
JardianceEmpagliflozin24$17,630
FarxigaDapagliflozin Propanediol22$13,206
EntrestoSacubitril/Valsartan18$11,401
BrilintaTicagrelor11$4,774
Metoprolol Succinate92$764
ClopidogrelClopidogrel Bisulfate67$255
Losartan Potassium21$241
Nifedipine ErNifedipine12$237
Nitroglycerin28$218
Bumetanide11$217
Spironolactone41$197
Isosorbide Mononitrate ErIsosorbide Mononitrate34$163
Atorvastatin Calcium34$153
Hydralazine Hcl20$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$604$17,98033 claims
Boehringer IngelheimJardiance$266$17,63024 claims
NovartisEntresto$15$11,40118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →